ARCHIVES

Arimidex Gets Full Approval For HR+ Early Breast Cancer

This article is from The Cancer Letter archive.

Vol. 28 No. 9 | September 30, 2005

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Would Give Clearer Picture Of C225 Role.

February 15, 2002

NCAB Delays Decision On Organ Site Program Until May Meeting

February 12, 1982

Non-Chemo Agents Added To Regimens For Lymphomas

January 26, 2007

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

March 28, 2014

No Issue Next Week

August 22, 1980

Congress Passes HHS Appropriations, Includes $9 Billion for NIH, $575 Million Delayed Funding

November 15, 1991